Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication?
作者信息
Ward Michael M
出版信息
Arthritis Rheum. 2011 Jun;63(6):1472-4. doi: 10.1002/art.30225.
Abstract
摘要
相似文献
1
Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication?柳氮磺胺吡啶治疗强直性脊柱炎：过时药物还是小众药物？
Arthritis Rheum. 2011 Jun;63(6):1472-4. doi: 10.1002/art.30225.
2
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.依那西普与柳氮磺胺吡啶治疗强直性脊柱炎患者的临床疗效及安全性：一项随机双盲试验
Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.
3
Conventional DMARDs in axial spondyloarthritis: wishful--rather than rational--thinking!轴性脊柱关节炎中的传统改善病情抗风湿药：一厢情愿而非理性思考！
Ann Rheum Dis. 2015 Jun;74(6):951-3. doi: 10.1136/annrheumdis-2014-206758. Epub 2015 Mar 20.
4
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials.分析所有依那西普治疗强直性脊柱炎临床试验中的葡萄膜炎发生率。
Ann Rheum Dis. 2010 Jan;69(1):226-9. doi: 10.1136/ard.2008.103192.
5
New-onset psoriasis associated with etanercept therapy.与依那西普治疗相关的新发银屑病。
J Dermatol. 2010 Apr;37(4):378-80. doi: 10.1111/j.1346-8138.2010.00789.x.
6
Efficacy of etanercept in ankylosing spondylitis hip lesions.
Joint Bone Spine. 2011 Oct;78(5):531-2. doi: 10.1016/j.jbspin.2011.03.023. Epub 2011 May 12.
7
Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.女性强直性脊柱炎患者：治疗研究中跨性别影响的分析。
Ann Rheum Dis. 2013 Jul;72(7):1221-4. doi: 10.1136/annrheumdis-2012-202431. Epub 2012 Dec 22.
8
The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.在强直性脊柱炎和未分化脊柱关节炎患者中，与传统合成疾病修饰抗风湿药物联合用药对 TNF 抑制剂药物生存的影响：一项全国性前瞻性研究的结果。
Ann Rheum Dis. 2015 Jun;74(6):970-8. doi: 10.1136/annrheumdis-2014-206616. Epub 2015 Feb 20.
9
Effect of etanercept on iritis in patients with ankylosing spondylitis.依那西普对强直性脊柱炎患者虹膜炎的疗效
Arthritis Rheum. 2004 Nov;50(11):3736-7. doi: 10.1002/art.20754.
10
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.在 ASCEND 试验中，依那西普或柳氮磺胺吡啶治疗的患者中，强直性脊柱炎疾病活动评分的敏感性和鉴别能力。
Rheumatology (Oxford). 2012 Oct;51(10):1894-905. doi: 10.1093/rheumatology/kes142. Epub 2012 Jul 6.
引用本文的文献
1
National pharmacological treatment trends for ankylosing spondylitis in South Korea: A national health insurance database study.韩国强直性脊柱炎的国家药物治疗趋势：一项国家健康保险数据库研究。
PLoS One. 2020 Oct 6;15(10):e0240155. doi: 10.1371/journal.pone.0240155. eCollection 2020.
本文引用的文献
1
Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.依那西普与柳氮磺胺吡啶治疗强直性脊柱炎患者的临床疗效及安全性：一项随机双盲试验
Arthritis Rheum. 2011 Jun;63(6):1543-51. doi: 10.1002/art.30223.
2
Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register.外周关节炎的存在和男性性别预测强直性脊柱炎抗肿瘤坏死因子治疗的持续时间：来自南瑞典关节炎治疗组登记处的观察性前瞻性队列研究。
Arthritis Care Res (Hoboken). 2010 Oct;62(10):1362-9. doi: 10.1002/acr.20258.
3
Treatments used by patients with ankylosing spondylitis comparison with the treatment preferences of rheumatologists.
J Clin Rheumatol. 1999 Feb;5(1):1-8. doi: 10.1097/00124743-199902000-00001.
4
How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured?强直性脊柱炎患者脊柱影像学进展的治疗效果应如何衡量？
Arthritis Rheum. 2005 Jul;52(7):1979-85. doi: 10.1002/art.21133.
5
Sulfasalazine for ankylosing spondylitis.柳氮磺胺吡啶用于治疗强直性脊柱炎。
Cochrane Database Syst Rev. 2005 Apr 18(2):CD004800. doi: 10.1002/14651858.CD004800.pub2.
6
Medication toxicity among patients with ankylosing spondylitis.强直性脊柱炎患者的药物毒性
Arthritis Rheum. 2002 Jun 15;47(3):234-41. doi: 10.1002/art.10399.
7
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.通过抑制肿瘤坏死因子α治疗强直性脊柱炎。
N Engl J Med. 2002 May 2;346(18):1349-56. doi: 10.1056/NEJMoa012664.
8
Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis.柳氮磺胺吡啶预防强直性脊柱炎相关性前葡萄膜炎
Eye (Lond). 2000 Jun;14 ( Pt 3A):340-3. doi: 10.1038/eye.2000.84.
9
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study.柳氮磺胺吡啶与安慰剂治疗血清阴性脊柱关节病的轴向和外周关节表现的比较：美国退伍军人事务部合作研究
Arthritis Rheum. 1999 Nov;42(11):2325-9. doi: 10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C.
10
Sulfasalazine and ankylosing spondylitis.柳氮磺胺吡啶与强直性脊柱炎
Ann Intern Med. 1984 Dec;101(6):878. doi: 10.7326/0003-4819-101-6-878_1.
Zotero 插件